

Last Updated July 2021

Published Original Articles

Astermark J, Holstein K, **Abajas YL**, Kearney S, Croteau SE, Liesner R, Funding E, Kempton CL, Acharya S, Lethagen S, LeBeau P, Bowen J, Berntorp E, Shapiro AD. The B-Natural study-The outcome of immune tolerance induction therapy in patients with severe haemophilia B. *Haemophilia*. 2021 Jun 12. doi: 10.1111/hae.14357. Epub ahead of print. PMID: 34118102.

Niss O, Lorschach RB, Berger M, Chonat S, McLemore M, Buchbinder D, McCavit T, Shaffer LG, Simpson J, Schwartz JH, Meznarich J, Emberesh M, Seu KG, Zhang W, Kalfa TA; *CDAR consortium. Congenital dyserythropoietic anemia type I: First report from the Congenital Dyserythropoietic Anemia Registry of North America (CDAR). *Blood Cells Mol Dis*. 2021 Mar;87:102534. doi: 10.1016/j.bcmd.2020.102534. Epub 2020 Dec 24. PMID: 33401150.

*CDAR consortium:

Ammar Husami, Theodosia Kalfa, Robert Lorschach, Carolyn Lutzko, Adam Nelson, Omar Niss, Charles Quinn, Katie G Seu, Wenying Zhang, Satheesh Chonat, David Buchbinder, Clarissa Johnson, Timothy McCavit, Linda G Shaffer, Jennifer A Rothman, Sweta Gupta, Mara Nuñez Toscano, Melissa Forouhar, Vinod K Gidvani-Diaz, James B Ball, Gavin D Roach, KayeLyn Wagner, Sam Milanovich, James Boyer, Jane Chawla, Christine Moore Smith, Adrienne Lee, Jessica Simpson, Jeffrey H Schwartz, Vlad C Radulescu, **Yasmina L Abajas**, A Kim Ritchey, Jessica Meznarich, Hunter R Underhill, Yaddanapudi Ravindranath, Morgan McLemore, Niketa C Shah

Shapiro AD, Ragni MV, Borhany M, **Abajas YL**, Tarantino MD, Holstein K, Croteau SE, Liesner R, Tarango C, Carvalho M, McGuinn C, Funding E, Kempton CL, Bidlingmaier C, Cohen A, Oldenburg J, Kearney S, Knoll C, Kuriakose P, Acharya S, Reiss UM, Kulkarni R, Witkop M, Lethagen S, Donfield S, LeBeau P, Berntorp E, Astermark J. Natural history study of factor IX deficiency with focus on treatment and complications (B-Natural). *Haemophilia*. 2021 Jan;27(1):49-59. doi: 10.1111/hae.14139. Epub 2020 Dec 5. PMID: 33278853.

Zimowski KL, McGuinn CE, **Abajas YL**, Schultz CL, Kaicker S, Batsuli, G. Use of plasma-derived factor X concentrate in neonates and infants with congenital factor X deficiency. *J Thromb Haemostasis*. 2020 Jul 2. doi: 10.1111/jth.14985. Online ahead of print.

Pei X, Shao W, Xing A, Askew C, Chen X, Cui C, **Abajas YL**, Gerber DA, Merricks EP, Nichols TC, Li W, Samulski RJ, Li C. Development of AAV Variants with Human Hepatocyte Tropism and Neutralizing Antibody Escape Capacity. *Mol Ther Methods Clin Dev*. 2020 Jun 3;18:259-268.

Kleiboer B, Nielsen B, Ma AD, **Abajas, YL**, Monroe DM, Key NS. Excessive breakthrough bleeding in haemophilia B patients on factor IX-albumin fusion protein prophylactic therapy: A single centre case series. *Haemophilia*. 2020 Jan: e23-e25.

Shao W, Pei X, Cui C, Askew C, Dobbins A, Chen X, **Abajas YL**, Gerber DA, Samulski RJ, Nichols TC, Li C. Superior human hepatocyte transduction with adeno-associated virus vector serotype 7. *Gene Ther*. 2019 Dec (12):504-514.

Mancuso ME, Bidlingmaier C, Mahlangu JN, Carcao M, Tosoletto A; Kurnik K, Blatny J, Castaman G, Linari S, Cid AR, Dargaud Y, Grabell J, James P, Holzhauer S, Kavakli K, Kenet G, Key N, **Abajas Y**, Ming

L, Mingot-Castellano ME, Ozelo M, Pabinger I, Santoro C, Tagliaferri A, Klukowska A. The predictive value of factor VIII/factor IX levels to define the severity of hemophilia: communication from the SSC of ISTH. *J Thromb Haemost*. 2018 Oct;16(10):2106-2110.

Sun J, Shao W, Chen X, Merricks EP, Wimsey L, **Abajas YL**, Niemeyer GP, Lothrop CD, Monahan PE, Samulski RJ, Nichols TC, Li, C. An observational study from long term AAV re-administration in two hemophilia dogs. *Mol Ther Methods Clin Dev*. 2018 Aug:257-257.

Okoye HC, Nielsen BI, Lee K, **Abajas YL**, Key NS, Rollins-Raval MA. DDAVP trial in discrepant non-severe haemophilia A patients. *Haemophilia* 2018 May [Epub ahead of print]

Sun J, Yuan Z, **Abajas YL**, Szollosi DE, Hu G, Hua B, Xiao X, Li C. A retrospective study of the cytokine profile changes in mice with FVIII inhibitor development after adeno-associated virus-mediated gene therapy in hemophilia A mouse model. *Human Gene Therapy* 2017 Oct:1-9.

Croteau SE, **Abajas YL**, Wolberg AS, Nielsen BI, Marx GR, Baird CW, Neufeld EJ, Monahan PE. Recombinant porcine factor VIII for high risk surgery in pediatric congenital hemophilia A with high-titer inhibitor. *Haemophilia* 2017 Mar;23(2):e93-e98.